RECRUITING CLINICAL TRIALS

Please contact our clinical research manager, Amy Ewald, MS, at (727) 323-0077

OPT-302-1004 Shore Study (North Tampa) – A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Lucentis, Compared with Lucentis Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)

2104 Atmosphere Study and RGX-314-3101 Ascent Study– A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD

BP41670 Burgundy Study – A Two-Part, Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7250284 following Intravitreal Administration of Unmasked Multiple Ascending Doses and Sustained Delivery from the Port Delivery System in Patients with Neovascular Age-Related Macular Degeneration

OTX-TKI-2023-AMD-301 SOL Study – A Phase 3, Multicenter, Double-Masked, Randomized, Parallel-Group Study
to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-
Related Macular Degeneration

UBX1325-04 Aspire Study – A Phase 2b, Prospective, Multicenter, Randomized, Double-Masked, Active Controlled Study to Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients with Diabetic Macular Edema.

No studies enrolling now

GR44277 Meerkat Study –  A Phase III, Randomized, Double-Masked, Sham-Controlled Study to Investigate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of RO7200220 Administered Intravitreally in Patients with Uveitis Macular Edema

81201887MDG2001 Janssen Study – A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Shamcontrolled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration

81201887NAP0001 Janssen Study – A Prospective Non-interventional Study to Assess Novel Functional Endpoints in Geographic Atrophy and Normal-sighted Participants

No studies enrolling now

KDK-1101-02 GION Study – A Phase 2, Double-masked, Randomized, Sham-controlled, Multiple-dose Study of the efficacy and safety of Intravitreal KUS121 in the Treatment of Non-Arteritic Central Retinal Artery Occlusion